Study One


A leading pharmaceutical company is using PHASTAR to provide support across approximately 45 studies. This includes design and setup of drug‑interaction, pharmacokinetic (e.g. patients with renal dysfunction), and long term safety studies; as well as support for phase III programmes and on‑going adaptive dose regimen studies. The work has included simulation projects e.g. to look at optimal analysis for a non-normal outcome variable. We are also working on a biomarker meta-analysis and generate the randomisation codes for a number of studies.